Review
Cell Biology
Ho-Yeop Lee, Ha Thi Nga, Jingwen Tian, Hyon-Seung Yi
Summary: HCC is a leading cause of cancer death worldwide, with its progression and metastasis closely linked to altered mitochondrial metabolism, including OXPHOS defects, increased ROS production, and UPRmt activation. Upregulation of FGF21 and GDF15 during UPRmt is positively correlated with liver cancer development, progression, and metastasis, while mitoribosomal defects contribute to HCC progression.
Article
Oncology
Chen Xue, Xinyu Gu, Lanjuan Li
Summary: This study identified four HCC subgroups based on immune system-related genes and validated five genes that may be used for an immune-based prognostic model for HCC treatment. The identified subgroups showed different clinical characteristics and immune cell enrichment scores, with Group 4 having the poorest outcomes. Additionally, highly expressed genes in Group 4 were enriched in elements of the WNT signaling pathway.
CANCER CELL INTERNATIONAL
(2021)
Article
Cell Biology
Dafeng Xu, Yu Wang, Jincai Wu, Yuliang Zhang, Zhehao Liu, Yonghai Chen, Jinfang Zheng
Summary: This study identified 64 common DEIGs enriched in tumor immunologic related signaling pathways and constructed a 5-gene signature risk model to predict the prognosis of HCC patients. Different immune expression characteristics lead to different prognostic outcomes. The model showed better performance compared to existing ones and had strong robustness across different cohorts.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Wei Chen, Romain Desert, Xiaodong Ge, Hui Han, Zhuolun Song, Sukanta Das, Dipti Athavale, Hong You, Natalia Nieto
Summary: This study identified 80 matrisome genes associated with HBV-related HCC, along with four significant matrisome gene modules and two patient subgroups. Additionally, four liver-specific matrisome genes involved in HBV-related HCC progression and prognosis were discovered.
HEPATOLOGY COMMUNICATIONS
(2021)
Article
Oncology
Tingbo Ye, Leilei Lin, Lulu Cao, Weiguo Huang, Shengzhe Wei, Yunfeng Shan, Zhongjing Zhang
Summary: Hepatocellular carcinoma patients with abnormal metabolism have worse prognosis. By studying metabolism-related pathways, the researchers classified hepatocellular carcinoma into two clusters and found that patients in one cluster had lower survival rates. They also developed a risk score model based on 11 differentially expressed metabolic genes, which accurately predicted overall survival in hepatocellular carcinoma patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Wei Yuan, Ran Tao, Da Huang, Weiming Yan, Guanxin Shen, Qin Ning
Summary: By systematically analyzing the molecular alterations in sorafenib-resistant HCC specimens and cells, four genes were identified as key factors related to sorafenib resistance, while immune cell infiltration was found to predict resistance as well. These findings suggest potential strategies for treating sorafenib-resistant HCC patients and advance the understanding of molecular mechanisms underlying resistance in liver cancer.
Review
Immunology
Fei-Qi Xu, Meng-Meng Dong, Zhi-Fei Wang, Li-Dong Cao
Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a common and difficult to diagnose malignant tumor with limited treatment options and poor prognosis. Aggressive cancer cells in HCC undergo extensive metabolic rewiring, leading to adaptation to the tumor microenvironment. Intratumoral heterogeneity (ITH), characterized by distinct genetic and phenotypic features in the same tumor region, is unique to malignant tumors and contributes to differences in tumor growth, chemotherapy resistance, and metabolic reprogramming. Understanding the associations between glucose metabolism reprogramming, tumoral heterogeneity, and HCC oncogenesis is crucial for better insights into HCC mechanisms.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Ying Zhang, He Ren, Chunting Zhang, Haihua Li, Qingzhi Guo, Haitao Xu, Lina Cui
Summary: This study investigates the prognostic value of ferroptosis-related genes (FRGs) in hepatocellular carcinoma (HCC) and their impact on tumor immune function. The findings suggest that these four pivotal FRGs play essential roles in tumor progression and are statistically significantly correlated with tumor-infiltrating immune cells and immune checkpoint expression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kenan Hao, Jincheng Li, Youao Zhang, Wei Zhao, Xiaojing Chen, Jiabin Xu, Ye Tian, Xinmin Li, Jianyu Fen, Xiaofeng He
Summary: This study systematically clarifies the functions of m6A-related lncRNAs in hepatocellular carcinoma and identifies their prognostic value in HCC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jianguo Wei, Shuqian Hou, Minhua Li, Xiaofei Yao, Li Wang, Zhen Zheng, Haiqian Mo, Yu Chen, Xiaolu Yuan
Summary: In this study, we conducted a comprehensive analysis of necroptosis-related genes in HCC and found that the NEC score can be effectively used to predict the prognosis of HCC patients and is associated with the response to immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Yinfang Li, Ling Zou, Xuejun Liu, Judong Luo, Hui Liu
Summary: A novel immune-related prognostic index (IRGPI) was developed based on transcriptomic profiles to predict immune infiltration level, response to ICI treatment, and overall survival in HCC patients. Low-risk patients had better survival compared to high-risk patients, with the latter being associated with higher TP53 mutation rates and immune-suppressing tumor microenvironment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yuan Yang, Guozhi Wu, Qiang Li, Ya Zheng, Min Liu, Lingshan Zhou, Zhaofeng Chen, Yuping Wang, Qinghong Guo, Rui Ji, Yongning Zhou
Summary: This study constructed a risk model based on five-gene signature by identifying angiogenesis-related immune genes affecting the prognosis of HCC. The model effectively predicted the survival outcome of HCC patients and showed promising clinical prediction value.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Cell Biology
Kunpeng Wang, Xinyi Chen, Chong Jin, Jinggang Mo, Hao Jiang, Bin Yi, Xiang Chen
Summary: The study identified immunoscore as a robust marker for predicting HCC patient survival, with excellent prognostic performance through multiple validations. Additionally, immunoscore showed superior predictive power in HCC treatment, and was significantly associated with immune cells and infiltration in the tumor microenvironment.
Article
Biology
Chuan Tian, Mubalake Abudoureyimu, Xinrong Lin, Hao Zhou, Xiaoyuan Chu, Rui Wang
Summary: The study identified a PSMD14-based immune prognostic signature for predicting the prognosis of HCC patients, providing potential new prognostic biomarkers and therapeutic targets for immunotherapy of HCC. Patients in the high-risk group had significantly poorer survival compared to those in the low-risk group, and calibration curves confirmed the accuracy of the predictive model.
Article
Immunology
Juan Lu, Chengbo Yu, Qiongling Bao, Xiaoqian Zhang, Jie Wang
Summary: Based on necroptosis-related genes, we classified hepatocellular carcinoma patients into three clusters, with C1 cluster having significantly shorter overall survival times. The proposed necroptosis signatures-based prognosis prediction model provides a novel approach in hepatocellular carcinoma survival prediction and clinical evaluation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yan Li, Chen Yang, Zhicheng Liu, Shangce Du, Susan Can, Hailin Zhang, Linmeng Zhang, Xiaowen Huang, Zhenyu Xiao, Xiaobo Li, Jingyuan Fang, Wenxin Qin, Chong Sun, Cun Wang, Jun Chen, Huimin Chen
Summary: Functional genetic immuno-oncology screens have been used to identify potential regulators in tumor-immune interactions. This study collected and analyzed the data from these screens and identified 105 regulator genes. A novel immune-oncology target called MON2 was also discovered. Furthermore, a signature named CTIS was developed to predict response to immune checkpoint blockade and improve the efficacy of immunotherapy agents.
Article
Biology
Chen Yang, Hailin Zhang, Mengnuo Chen, Siying Wang, Ruolan Qian, Linmeng Zhang, Xiaowen Huang, Jun Wang, Zhicheng Liu, Wenxin Qin, Cun Wang, Hualian Hang, Hui Wang
Summary: Pharmacologic perturbation projects have generated expression data for computational therapeutic discovery, but optimal methodologies and parameters are still unclear. This study developed benchmarking standards and determined an optimal approach for drug retrieval. The candidate agent HHT was validated and shown to have therapeutic effects on liver cancer.
Editorial Material
Oncology
Yuchen Guo, Yangyang Zhou, Wenxin Qin
CANCER BIOLOGY & MEDICINE
(2022)
Article
Oncology
Zhuoan Cheng, Chunlai Lu, Hui Wang, Ning Wang, Shaohua Cui, Chengtao Yu, Cun Wang, Qiaozhu Zuo, Siying Wang, Yuanyuan Lv, Ming Yao, Liyan Jiang, Wenxin Qin
Summary: The study found that LHFPL3-AS2 is a novel long noncoding RNA that is significantly decreased in non-small cell lung cancer (NSCLC) tissues. Low levels of LHFPL3-AS2 expression were highly correlated with poor overall survival, TNM stage, and metastasis of NSCLC patients. Enhanced expression of LHFPL3-AS2 inhibited NSCLC invasion and metastasis.
Article
Multidisciplinary Sciences
Zhicheng Liu, Dongxu Lin, Yi Zhou, Linmeng Zhang, Chen Yang, Bin Guo, Feng Xia, Yan Li, Danyang Chen, Cun Wang, Zhong Chen, Chao Leng, Zhenyu Xiao
Summary: In this study, large-scale genomic profiles from ccRCC cohorts were analyzed to identify synthetic lethality pairs and potential medical targets. BRD4 and PRKDC were identified as novel targets for patients with BAP1 mutations, and two drugs, BI-2536 and PI-103, were found to have therapeutic potential for BAP1 mutant tumors. Overall, this study provides insight into ccRCC mutation patterns and offers new opportunities for personalized cancer treatment.
SCIENTIFIC REPORTS
(2022)
Letter
Cell Biology
Xuhui Ma, Shanshan Wu, Botai Li, Qianqian Zhang, Jianming Zhang, Wenming Liu, Hexin Yan, Rene Bernards, Wenxin Qin, Cun Wang
Review
Gastroenterology & Hepatology
Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, Rene Bernards, Wenxin Qin, Cun Wang
Summary: This review summarizes the latest clinical advances in the treatment of advanced hepatocellular carcinoma, including molecular-targeted monotherapies, immuno-oncology monotherapies, combination therapies and novel therapeutic approaches.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Genetics & Heredity
Chen Yang, Senquan Zhang, Zhuoan Cheng, Zhicheng Liu, Linmeng Zhang, Kai Jiang, Haigang Geng, Ruolan Qian, Jun Wang, Xiaowen Huang, Mo Chen, Zhe Li, Wenxin Qin, Qiang Xia, Xiaonan Kang, Cun Wang, Hualian Hang
Summary: This study proposes a new sampling strategy to investigate the heterogeneity of hepatocellular carcinoma (HCC) and reveals the significant impact of spatial distribution on heterogeneity estimation. The findings provide insights into the complex phenotypes of HCC and offer a new risk stratification method to predict patient outcomes.
Article
Medicine, General & Internal
Yangyang Zhou, Siying Wang, Wei Wu, Jing Ling, Haoyu Li, Qi Jia, Jiaojiao Zheng, Xingling Zheng, Ruobing Yu, Qiangxin Wu, Yaoping Shi, Cor Lieftink, Roderick L. Beijersbergen, Shengxian Yuan, Rene Bernards, Haojie Jin, Wenxin Qin
Summary: This study identified mitochondrial translation-related genes associated with proliferation in liver cancer cells. Tigecycline disrupted mitochondrial translation process and induced respiratory chain deficiency, showing therapeutic potential for liver cancer. MEK inhibitors were identified as synergistic drugs to Tigecycline-insensitive liver cancer cells. Blockade of EGFR-ERK1/2-MYC cascade combined with Tigecycline could be a potential therapeutic strategy for liver cancer.
Article
Oncology
Liqin Wang, Haojie Jin, Fleur Jochems, Siying Wang, Cor Lieftink, Isabel Mora Martinez, Giulia De Conti, Finn Edwards, Rodrigo Leite de Oliveira, Arnout Schepers, Yangyang Zhou, Jiaojiao Zheng, Wei Wu, Xingling Zheng, Shengxian Yuan, Jing Ling, Kathy Jastrzebski, Matheus Dos Santos Dias, Ji-Ying Song, Patrick N. H. Celie, Hideo Yagita, Ming Yao, Weiping Zhou, Roderick L. Beijersbergen, Wenxin Qin, Rene Bernards
Summary: Senolytics are drugs that kill senescent cells, and this study identifies cFLIP as a common vulnerability of senescent cancer cells. Activation of DR5 signaling can lead to efficient killing of senescent cancer cells and non-senescent cells can be sensitized to DR5 agonist through a bystander effect mediated by secretion of cytokines. Animal models confirm the effectiveness of combining pro-senescence therapy with DR5 activation.
Article
Cell Biology
Qiaozhu Zuo, Yongkang Yang, Yajing Lyu, Chen Yang, Chelsey Chen, Shaima Salman, Tina Yi-Ting Huang, Elizabeth E. Wicks, Walter Jackson, Emmanuel Datan, Wenxin Qin, Gregg L. Semenza
Summary: Intratumoral hypoxia promotes breast cancer progression and is associated with cancer mortality. This study reveals that Plexin B3 (PLXNB3) is highly expressed in estrogen receptor-negative breast cancer and is a direct target gene of hypoxia-inducible factor 1 (HIF-1). PLXNB3 is correlated with HIF-1a immunohistochemistry, breast cancer grade and stage, and patient mortality. Mechanistically, PLXNB3 is required for hypoxia-induced signaling and breast cancer cell migration, invasion, and cancer stem cell specification. Knockdown of PLXNB3 impairs tumor formation and lung metastasis in orthotopic breast cancer mouse models.
Letter
Biochemistry & Molecular Biology
Linmeng Zhang, Ning Tang, Chen Yang, Haigang Geng, Hualian Hang, Wenxin Qin, Cun Wang
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)